Stratagene Expects 7 Percent Rise in Q4 Revenues;
Licenses microRNA Sequences from Max Planck
 
Stratagene last week said that it expects fourth-quarter revenue to be around $24.7 million, or 7 percent better than last year’s pro forma revenue of $23 million for the same period.
 
The uptick came largely from sales of the company’s QPCR products and reagents, which were up 7 percent, and from allergy diagnostics products, which were up 23 percent, Stratagene said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.